Why Axsome Therapeutics (AXSM) Is Getting Attention Today

What the new Phase 3 SUMMIT trial means for Axsome Therapeutics stock

Axsome Therapeutics (AXSM) has dosed the first patient in its SUMMIT Phase 3 trial of AXS-05 for smoking cessation, bringing a late stage program in a new indication into focus for investors.

The SUMMIT study will compare AXS-05 with bupropion and placebo over about 12 weeks in adult smokers, with smoking abstinence at the end of treatment as the primary outcome. For readers tracking Axsome Therapeutics, this trial sits alongside the company’s existing approvals for AXS-05 in major depressive disorder and agitation associated with dementia due to Alzheimer’s disease. It remains an investigational therapy in smoking cessation.

The Axsome Therapeutics share price is at US$198.52 after a period where the 30 day share price return fell 8.93% and the 90 day share price return declined 14.98%. However, the 1 year total shareholder return is 60.78% and the 5 year total shareholder return is very large. This suggests that long term holders have still seen strong compounding, even as recent momentum has cooled around events such as the SUMMIT trial initiation.

Compare Axsome Therapeutics with a hand picked group of CNS and healthcare stocks that currently screen as 19 high quality undiscovered gems.

After a sharp pullback set against very strong multiyear returns, investors are left weighing whether Axsome Therapeutics is simply catching its breath or if sentiment has run ahead of what the current business supports.

Most Popular Narrative: 29.7% Undervalued

The most followed Axsome Therapeutics narrative puts fair value at $282.51, well above the last close at $198.52. This frames the SUMMIT trial within a broader growth story.

Axsome's portfolio is expanding with the launch of SYMBRAVO for migraine and ongoing robust growth of Auvelity and Sunosi, reflecting increased societal prioritization of mental health and CNS disorders, which could drive further top-line revenue growth as these long-term demand trends play out globally.

Read the complete narrative.

Want to see why this narrative supports a higher fair value for Axsome Therapeutics? The projection leans heavily on rapid revenue expansion, margin uplift, and a richer earnings multiple.

The fair value view rests on Axsome Therapeutics growing revenue and earnings quickly, lifting margins from current loss making levels and supporting a higher valuation multiple than the wider pharmaceuticals sector over time.

Result: Fair Value of $282.51 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Axsome Therapeutics still faces execution risk if Auvelity, Sunosi or Symbravo grow more slowly than analysts expect, or if ongoing net losses pressure future funding options.

Find out about the key risks to this Axsome Therapeutics narrative.

Next Steps

With sentiment around Axsome Therapeutics clearly mixed, it makes sense to review the facts for yourself and move quickly to shape your own view. Start by checking the 3 key rewards

Looking for more Axsome Therapeutics investment ideas?

If Axsome Therapeutics interests you, do not stop your research here. Use the tools available to compare it with other opportunities and pressure test your thesis.

• Spot potential turnaround stories by scanning the 22 elite penny stocks with strong financials that combine smaller market caps with specific financial filters.
• Zero in on companies that currently look attractively priced relative to fundamentals by reviewing the 45 high quality undervalued stocks.
• Focus on steadier profiles and prioritise capital preservation by checking the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com